Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenic agents.

W D Klohs1, J M Hamby

  • 1Department of Drug Development, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI 48105, USA.

Current Opinion in Biotechnology
|December 22, 1999
PubMed
Summary

New anti-angiogenic compounds show promise for cancer therapy. These agents target tumor blood vessel formation, potentially offering effective treatment with reduced side effects and drug resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

Journal of medicinal chemistry·2001
Same author

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

Journal of medicinal chemistry·2000
Same author

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors.

Pharmacology & therapeutics·1999
Same author

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.

Journal of medicinal chemistry·1999
Same author

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

Journal of medicinal chemistry·1998
Same author

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

The EMBO journal·1998

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Discovery

Background:

  • Tumor growth and metastasis depend on angiogenesis, the formation of new blood vessels.
  • Targeting angiogenesis offers a therapeutic strategy with potential for reduced toxicity and drug resistance compared to traditional chemotherapy.
  • Vascular endothelial cells (ECs) have a slow turnover rate, making them attractive targets for anti-cancer agents.

Purpose of the Study:

  • To identify and evaluate novel agents that inhibit tumor-induced angiogenesis.
  • To assess the anti-angiogenic and anti-tumor activities of new therapeutic compounds.

Main Methods:

  • Investigated small molecules and antibodies interfering with endothelial cell signaling, migration, and differentiation.
  • Reported on the anti-angiogenic and anti-tumor effects of three specific compounds: ZD4190, SU6668, and PD 0173073.

Main Results:

  • Three novel compounds (ZD4190, SU6668, PD 0173073) demonstrated significant and selective anti-angiogenic activity.
  • These compounds also exhibited notable anti-tumor activity in preclinical studies.

Conclusions:

  • The development of targeted anti-angiogenic agents represents a promising avenue for cancer treatment.
  • ZD4190, SU6668, and PD 0173073 are potential candidates for further investigation as anti-cancer therapeutics.

Related Experiment Videos